

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known 152728	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	IA No. PCT/SE2003/01399
		Filing Date	Intl Filing Date 9/8/2003
		First Named Inventor	Peter BERNSTEIN
		Art Unit	
		Examiner Name	
(Use as many sheets as necessary)		Attorney Docket Number	100829-1P US
Sheet	1	of	1

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴			
/D.O./	GB	2347423	A	09/06/2000	Merck Sharp & Dohme	clms 8, 16-18, pg 38, ln 23-26
/D.O./	WO	9519344	A1	07/20/1995	Merck Sharp & Dohme	the claims, pg 18, ln 12 - pg 19, ln 20
/D.O./	WO	9410165	A1	05/11/1994	Merck Sharp & Dohme	the claims, pg 20, ln 16 - pg 21, ln 29

Examiner Signature	/David O Dell/	Date Considered	10/30/2007
--------------------	----------------	-----------------	------------

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known 10/527280	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	IA NO. PCT/SE2003/001399
(Use as many sheets as necessary)				Filing Date	Intl. Filing Ssept. 8, 2003
				First Named Inventor	Peter BERNSTEIN
				Art Unit	
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	100829-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/D.O./		GRAEME I. STEVENSON ET AL, "4,4-Disubstituted Piperidines: A New Class of NK1 Antagonist," J. Med. Chem., Vol. 38 (No. 8), p. 1264-1266, (1995).	
/D.O./		GRAEME I. STEVENSON ET AL, "4,4 Disubstituted Piperidine High-Affinity NK1, Antagonists: Structure-Activity Relationships and in Vivo Activity," J. Med. Chem., Vol. 41 (No. 23), p. 4623-4635, (November 23, 1998).	
/D.O./		JASON M. ELLIOTT ET AL, "4,4-Disubstituted Cyclohexylamine NK1 Receptor Antagonists I," Bioorganic & Medicinal Chemistry Letters, Vol. 12 (No. 13), p. 1755-1758, table 3, compound nos. 23, 27 (July 8, 2002).	
/D.O./		THOMAS RYCKMANS ET AL, "First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: Synthesis and SAR of a New Class of Potential Antidepressants," Bioorganic & Medicinal Chemistry Letters, Vol. 12 (No. 2), p. 261-264, (2002).	

Examiner Signature	/David O Dell/	Date Considered	10/30/2007
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.